Pub Date : 2024-05-08DOI: 10.1515/oncologie-2024-0056
Chenlu Li, Tao Zhang, Mi Yan, Yan Chen, Ruchao Nan, Jun Chen, Xiaoyu Wang
This research aims to explore the relationship between glutathione peroxidase (GPX) expression variations in papillary renal cell carcinoma (pRCC) and patient survival, while also developing and evaluating a customized survival prediction model based on GPX. The transcriptomic dataset, including clinical parameters and GPX expression levels, is sourced from The Cancer Genome Atlas (TCGA) database, comprising 290 individuals diagnosed with pRCC. We utilized a univariate Cox regression model to select differentially expressed genes. Subsequently, we calculated risk scores through the least absolute shrinkage and selection operator (LASSO) regression. Based on the median risk score, patients were categorized into high and low-risk groups, establishing a prognostic risk model. Following this, the relationship between the risk model and the survival of pRCC patients was revealed through Kaplan–Meier survival curve analysis. The sensitivity and specificity of the predictive model were evaluated using receiver operating characteristic (ROC) curve analysis. Furthermore, chemotherapy drug sensitivity analysis was conducted on patients in the high and low-risk groups. A risk-scoring model was built by selecting GPX7 and GPX8. Compared to the low-risk group, individuals in the high-risk category showed significantly reduced overall survival rates (p=0.018). Additionally, validation results demonstrated the model’s good predictive accuracy. The risk-scoring model constructed based on GPX family genes provides an innovative biomarker for forecasting the prognosis of pRCC and serves as a reference for individualized therapy in pRCC.
{"title":"Exploring genes within the glutathione peroxidase family as potential predictors of prognosis in papillary renal cell carcinoma","authors":"Chenlu Li, Tao Zhang, Mi Yan, Yan Chen, Ruchao Nan, Jun Chen, Xiaoyu Wang","doi":"10.1515/oncologie-2024-0056","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0056","url":null,"abstract":"\u0000 \u0000 \u0000 This research aims to explore the relationship between glutathione peroxidase (GPX) expression variations in papillary renal cell carcinoma (pRCC) and patient survival, while also developing and evaluating a customized survival prediction model based on GPX.\u0000 \u0000 \u0000 \u0000 The transcriptomic dataset, including clinical parameters and GPX expression levels, is sourced from The Cancer Genome Atlas (TCGA) database, comprising 290 individuals diagnosed with pRCC. We utilized a univariate Cox regression model to select differentially expressed genes. Subsequently, we calculated risk scores through the least absolute shrinkage and selection operator (LASSO) regression. Based on the median risk score, patients were categorized into high and low-risk groups, establishing a prognostic risk model. Following this, the relationship between the risk model and the survival of pRCC patients was revealed through Kaplan–Meier survival curve analysis. The sensitivity and specificity of the predictive model were evaluated using receiver operating characteristic (ROC) curve analysis. Furthermore, chemotherapy drug sensitivity analysis was conducted on patients in the high and low-risk groups.\u0000 \u0000 \u0000 \u0000 A risk-scoring model was built by selecting GPX7 and GPX8. Compared to the low-risk group, individuals in the high-risk category showed significantly reduced overall survival rates (p=0.018). Additionally, validation results demonstrated the model’s good predictive accuracy.\u0000 \u0000 \u0000 \u0000 The risk-scoring model constructed based on GPX family genes provides an innovative biomarker for forecasting the prognosis of pRCC and serves as a reference for individualized therapy in pRCC.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140998574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-24DOI: 10.1515/oncologie-2023-0586
Nazmin Ahmed, G. Scalia, G. Umana, Sruthi Ranganathan, Samsul Arifin, Md. Isma Azam, Mohammad Morshad Alam, M. A. Azab, Minaam Farooq, Daniel Encarnación-Santos, Bashir Ahammed, O. Atallah, Bipin Chaurasia
Olfactory Nerve Schwannomas (ONS) affect cranial nerve I (CN I), responsible for the sense of smell. This systematic review aims to comprehensively examine the risk factors, etiology, clinical presentation, and management of ONS by analyzing 44 case reports/series published from 1978 to 2022. Our systematic review utilized a comprehensive search strategy across various scientific databases, including PubMed, Scopus, and Web of Science in March 2023. The inclusion and exclusion criteria included minimum information on demographics (i.e., age), clinical presentation, syndrome, area involved, and extent of resection. The selected articles were case reports, so there is no question about bias. Articles were meticulously reviewed for the above information and underwent both qualitative and quantitative analysis. A total of 44 case reports/series, consisting of 45 patients, were included in this study (mean: 38.45). The anterior cranial fossa was the most frequently involved area (48 %). The most common surgical procedure was bifrontal craniotomy (n=16), followed by left frontal craniotomy (n=7). Approximately 95.5 % of patients underwent Gross Total Resection (GTR), while 4.5 % had Subtotal Resection (STR). Radiotherapy was applied to two patients. Olfactory function varied, with 35.5 % preserving it and 28.88 % experiencing damage or loss. Positive outcomes were observed in approximately 66.6 % of cases, with complications reported in 15 % of instances, including cerebrospinal fluid (CSF) rhinorrhea and diplopia. Long-term follow-up and regular screening of patients are imperative. Further research is essential to elucidate the precise pathogenesis and to develop improved treatment modalities for ONS. This review provides a comprehensive overview of the current state of knowledge regarding ONS; however, as the disease is very rare, only case reports are available as a primary study, making it difficult to reach a strong conclusion.
{"title":"Olfactory Nerve Schwannoma: a case series with a systematic review of the literature focusing risk factors, etiology, clinical presentation, and management","authors":"Nazmin Ahmed, G. Scalia, G. Umana, Sruthi Ranganathan, Samsul Arifin, Md. Isma Azam, Mohammad Morshad Alam, M. A. Azab, Minaam Farooq, Daniel Encarnación-Santos, Bashir Ahammed, O. Atallah, Bipin Chaurasia","doi":"10.1515/oncologie-2023-0586","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0586","url":null,"abstract":"\u0000 \u0000 \u0000 Olfactory Nerve Schwannomas (ONS) affect cranial nerve I (CN I), responsible for the sense of smell. This systematic review aims to comprehensively examine the risk factors, etiology, clinical presentation, and management of ONS by analyzing 44 case reports/series published from 1978 to 2022.\u0000 \u0000 \u0000 \u0000 Our systematic review utilized a comprehensive search strategy across various scientific databases, including PubMed, Scopus, and Web of Science in March 2023. The inclusion and exclusion criteria included minimum information on demographics (i.e., age), clinical presentation, syndrome, area involved, and extent of resection. The selected articles were case reports, so there is no question about bias. Articles were meticulously reviewed for the above information and underwent both qualitative and quantitative analysis.\u0000 \u0000 \u0000 \u0000 A total of 44 case reports/series, consisting of 45 patients, were included in this study (mean: 38.45). The anterior cranial fossa was the most frequently involved area (48 %). The most common surgical procedure was bifrontal craniotomy (n=16), followed by left frontal craniotomy (n=7). Approximately 95.5 % of patients underwent Gross Total Resection (GTR), while 4.5 % had Subtotal Resection (STR). Radiotherapy was applied to two patients. Olfactory function varied, with 35.5 % preserving it and 28.88 % experiencing damage or loss. Positive outcomes were observed in approximately 66.6 % of cases, with complications reported in 15 % of instances, including cerebrospinal fluid (CSF) rhinorrhea and diplopia.\u0000 \u0000 \u0000 \u0000 Long-term follow-up and regular screening of patients are imperative. Further research is essential to elucidate the precise pathogenesis and to develop improved treatment modalities for ONS. This review provides a comprehensive overview of the current state of knowledge regarding ONS; however, as the disease is very rare, only case reports are available as a primary study, making it difficult to reach a strong conclusion.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140664745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-19DOI: 10.1515/oncologie-2024-0020
Chunxiu Peng, Zhijian Ye, Jintong Na, Xiyu Liu, Zhiyong Zhang
Hepatocellular carcinoma is one of the most common malignant tumors in the world with complex etiology, high tumor heterogeneity, and low efficacy of treatment. The establishment of an animal model that is close to the clinical situation of hepatocellular carcinoma and can be successfully modeled many times is of great significance to the study of the pathogenesis, diagnosis and treatment of hepatocellular carcinoma. We used Diethylnitrosamine (DEN) to induce hepatocellular carcinoma in rodents and compared four models of DEN-induced hepatocellular carcinoma. Group C (Control): rats were fed a standard laboratory rat diet and freely drank normal water. Group P (Peritoneal injection): rats were administered an IP injection (50 mg/kg/week) between 5 and 23 weeks after birth. Ten microliter of DEN solution would be injected per g of rat. Group O (DEN-Fed group): rats were allowed unrestricted access to water contaminated with 0.01 % DEN between the ages of 7 and 15 weeks. 0.2 mL of DEN drinking water was consumed per gram of rat. Group P+O (Combined peritoneal injection and Oral feeding): rats were administered an IP injection (50 mg/kg) at weeks 3 and 5 post-birth, and they freely drank water contaminated with 0.012 % DEN between weeks 7 and 14 post-birth. We used an ultrasound scan, biochemical testing, haematoxylin, and eosin staining, Masson staining, Wolf scarlet staining, Ki67, CD34, a-SMA, CD8, and CD68 staining to compare between groups. Liver dissection and ultrasound scan showed that compared to other groups, the liver of Group P+O was darker in color, with more grey-white cancer nodules and larger localized tumors, and the structure of the tumors was slightly disorganized, with the elastography hardness of the middle lobe and the right lobe was slightly increased. The alanine aminotransferase and total bilirubin of Group P+O were higher than those of Group O but lower than those of Group P. Haematoxylin and eosin staining showed that the tumors of Group P+O were large, with large tumor cords and pseudo-glandular, the degree of differentiation was medium and surrounded by more fatty lesions. We conclude that combined DEN treatment is more effective, stable, and has the advantage of multiple modalities, leading to faster tumor formation.
{"title":"Establishment and refinement of a DEN-induced hepatocellular carcinoma model in rats","authors":"Chunxiu Peng, Zhijian Ye, Jintong Na, Xiyu Liu, Zhiyong Zhang","doi":"10.1515/oncologie-2024-0020","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0020","url":null,"abstract":"\u0000 \u0000 \u0000 Hepatocellular carcinoma is one of the most common malignant tumors in the world with complex etiology, high tumor heterogeneity, and low efficacy of treatment. The establishment of an animal model that is close to the clinical situation of hepatocellular carcinoma and can be successfully modeled many times is of great significance to the study of the pathogenesis, diagnosis and treatment of hepatocellular carcinoma.\u0000 \u0000 \u0000 \u0000 We used Diethylnitrosamine (DEN) to induce hepatocellular carcinoma in rodents and compared four models of DEN-induced hepatocellular carcinoma. Group C (Control): rats were fed a standard laboratory rat diet and freely drank normal water. Group P (Peritoneal injection): rats were administered an IP injection (50 mg/kg/week) between 5 and 23 weeks after birth. Ten microliter of DEN solution would be injected per g of rat. Group O (DEN-Fed group): rats were allowed unrestricted access to water contaminated with 0.01 % DEN between the ages of 7 and 15 weeks. 0.2 mL of DEN drinking water was consumed per gram of rat. Group P+O (Combined peritoneal injection and Oral feeding): rats were administered an IP injection (50 mg/kg) at weeks 3 and 5 post-birth, and they freely drank water contaminated with 0.012 % DEN between weeks 7 and 14 post-birth. We used an ultrasound scan, biochemical testing, haematoxylin, and eosin staining, Masson staining, Wolf scarlet staining, Ki67, CD34, a-SMA, CD8, and CD68 staining to compare between groups.\u0000 \u0000 \u0000 \u0000 Liver dissection and ultrasound scan showed that compared to other groups, the liver of Group P+O was darker in color, with more grey-white cancer nodules and larger localized tumors, and the structure of the tumors was slightly disorganized, with the elastography hardness of the middle lobe and the right lobe was slightly increased. The alanine aminotransferase and total bilirubin of Group P+O were higher than those of Group O but lower than those of Group P. Haematoxylin and eosin staining showed that the tumors of Group P+O were large, with large tumor cords and pseudo-glandular, the degree of differentiation was medium and surrounded by more fatty lesions.\u0000 \u0000 \u0000 \u0000 We conclude that combined DEN treatment is more effective, stable, and has the advantage of multiple modalities, leading to faster tumor formation.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-19DOI: 10.1515/oncologie-2024-0036
Drenushe Zhuri, S. Yalçıntepe
Endometrial cancer (EC) is one of the most frequent invasive cancers of the female genital tract, and despite the rising incidence of EC worldwide and the poor overall survival of patients, no viable blood-based biomarker exists to detect and track EC recurrence during routine follow-up. Identification of new genetic targets and biomarkers linked to enhanced recurrence risk and medication response is a primary clinical issue in the treatment of advanced endometrial cancer. In this regard, liquid biopsy has become a breakthrough in human cancers. A liquid biopsy blood test has the advantage of being more sensitive than traditional imaging and is a minimally invasive complement to needle or excision biopsies of tissue. Here in this article, we discussed the advances and limitations of liquid biopsy. The detection of biomarkers and variations in liquid biopsy may help the diagnostic process of endometrial cancer cases.
{"title":"Liquid biopsy as a new era in endometrial cancer","authors":"Drenushe Zhuri, S. Yalçıntepe","doi":"10.1515/oncologie-2024-0036","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0036","url":null,"abstract":"\u0000 Endometrial cancer (EC) is one of the most frequent invasive cancers of the female genital tract, and despite the rising incidence of EC worldwide and the poor overall survival of patients, no viable blood-based biomarker exists to detect and track EC recurrence during routine follow-up. Identification of new genetic targets and biomarkers linked to enhanced recurrence risk and medication response is a primary clinical issue in the treatment of advanced endometrial cancer. In this regard, liquid biopsy has become a breakthrough in human cancers. A liquid biopsy blood test has the advantage of being more sensitive than traditional imaging and is a minimally invasive complement to needle or excision biopsies of tissue. Here in this article, we discussed the advances and limitations of liquid biopsy. The detection of biomarkers and variations in liquid biopsy may help the diagnostic process of endometrial cancer cases.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140683608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Choriocarcinoma is a highly malignant and aggressive trophoblastic tumor. In our previous study, we discovered that the speckle-type POZ protein (SPOP), which recognizes substrates of E3 ubiquitin ligase, plays a crucial role in trophoblast-derived choriocarcinoma cell lines. Therefore, we investigated the correlation between SPOP and the substrate kinesin-like protein KIF23, as well as the role of KIF23 in choriocarcinoma cells. We constructed JAR cells overexpressing SPOP using lentiviral vectors and subsequently screened the related proteins through ubiquitination-modified quantitative proteomic analysis. The relationship between KIF23 and SPOP was determined using western blotting, and CCK-8, plate cloning, flow cytometry, and Transwell assays were used to investigate the effects of KIF23 and SPOP/KIF23. We identified the KIF23 protein and observed that SPOP promoted its degradation. The abundance of KIF23 increased after the addition of the protease inhibitor MG132. KIF23 was highly expressed in choriocarcinoma cells. Compared with JAR cells transfected with NC–small-interfering RNA (siRNA), the proliferation, invasion, migration, and percentage of G0/G1 cells in the KIF23-siRNA group were significantly lower, and the activation of the Akt/GSK3β signaling pathway was markedly attenuated. Additionally, the sh-SPOP+KIF23-siRNA group exhibited significantly inhibited JAR cell proliferation, invasion, and migration, along with clearly attenuated activation of the Akt/GSK3β signaling pathway. SPOP attenuates the proliferation, invasion, and migration of choriocarcinoma JAR cells by promoting KIF23 degradation.
{"title":"SPOP attenuates the proliferation, invasion, and migration of choriocarcinoma JAR cells by promoting KIF23 degradation","authors":"Chunli Zhou, Yiyu Chen, Hairong Jiang, Chenchen Xia, Xiaohan Yuan, Qiubo Yu","doi":"10.1515/oncologie-2023-0595","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0595","url":null,"abstract":"\u0000 \u0000 \u0000 Choriocarcinoma is a highly malignant and aggressive trophoblastic tumor. In our previous study, we discovered that the speckle-type POZ protein (SPOP), which recognizes substrates of E3 ubiquitin ligase, plays a crucial role in trophoblast-derived choriocarcinoma cell lines. Therefore, we investigated the correlation between SPOP and the substrate kinesin-like protein KIF23, as well as the role of KIF23 in choriocarcinoma cells.\u0000 \u0000 \u0000 \u0000 We constructed JAR cells overexpressing SPOP using lentiviral vectors and subsequently screened the related proteins through ubiquitination-modified quantitative proteomic analysis. The relationship between KIF23 and SPOP was determined using western blotting, and CCK-8, plate cloning, flow cytometry, and Transwell assays were used to investigate the effects of KIF23 and SPOP/KIF23.\u0000 \u0000 \u0000 \u0000 We identified the KIF23 protein and observed that SPOP promoted its degradation. The abundance of KIF23 increased after the addition of the protease inhibitor MG132. KIF23 was highly expressed in choriocarcinoma cells. Compared with JAR cells transfected with NC–small-interfering RNA (siRNA), the proliferation, invasion, migration, and percentage of G0/G1 cells in the KIF23-siRNA group were significantly lower, and the activation of the Akt/GSK3β signaling pathway was markedly attenuated. Additionally, the sh-SPOP+KIF23-siRNA group exhibited significantly inhibited JAR cell proliferation, invasion, and migration, along with clearly attenuated activation of the Akt/GSK3β signaling pathway.\u0000 \u0000 \u0000 \u0000 SPOP attenuates the proliferation, invasion, and migration of choriocarcinoma JAR cells by promoting KIF23 degradation.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140714185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-11DOI: 10.1515/oncologie-2024-0079
Zhipeng Yao, He Huang, Sihan Zhang, Shaogang Wang, Qidong Xia, Zheng Liu
The 2bRAD sequencing for Microbiome (2bRAD-M) represents an innovative and streamlined approach for the reconstruction of microbial profiles at the species level. In our investigation, we conducted 2bRAD-M analysis to characterize the microbiome of bladder tissue in patients with muscle-invasive bladder cancer (MIBC). 15 tumor tissues and 15 paired para-carcinoma tissues were obtained from the bladder excised during surgery. 2bRAD-M sequencing was used to assess the abundance of microorganisms in samples. The microbial community structure and biodiversity, as assessed at varying taxonomic ranks, exhibited a high degree of similarity between the tumor and paired non-tumor tissues. At the genus level, we observed a notably elevated abundance of Brachybacterium and Haloparvum, coupled with a diminished abundance of Anoxybacillus, Anoxybacillu_A, Deinococcus, NCEH01, and Pseudoxanthomonas_A in the tumor tissues. Meanwhile, at the species level, the non-tumor tissues exhibited an enrichment of Anoxybacillus_A rupiensis, Anoxybacillus flavithermus_G, Klebsiella quasipneumoniae, NCEH01 sp002304505, and Pseudoxanthomonas_A sp004284195. Linear discriminant analysis effect size (LEfSe) identified 29 discriminative features, characterized by significant variations (p<0.5, LDA≥2.0) in relative abundance between the two groups. Furthermore, an analysis of functional predictions utilizing Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) also uncovered disparities in the microbial functional composition. This study identified several microorganisms that exhibit differences between MIBC tumor tissue and adjacent non-tumor tissue using 2bRAD-M sequencing, providing some insights into the potential association between the bladder microbiome and cancer.
{"title":"Exploring the bladder tissue microbiome in patients with muscle-invasive bladder cancer using 2bRAD-M sequencing","authors":"Zhipeng Yao, He Huang, Sihan Zhang, Shaogang Wang, Qidong Xia, Zheng Liu","doi":"10.1515/oncologie-2024-0079","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0079","url":null,"abstract":"\u0000 \u0000 \u0000 The 2bRAD sequencing for Microbiome (2bRAD-M) represents an innovative and streamlined approach for the reconstruction of microbial profiles at the species level. In our investigation, we conducted 2bRAD-M analysis to characterize the microbiome of bladder tissue in patients with muscle-invasive bladder cancer (MIBC).\u0000 \u0000 \u0000 \u0000 15 tumor tissues and 15 paired para-carcinoma tissues were obtained from the bladder excised during surgery. 2bRAD-M sequencing was used to assess the abundance of microorganisms in samples.\u0000 \u0000 \u0000 \u0000 The microbial community structure and biodiversity, as assessed at varying taxonomic ranks, exhibited a high degree of similarity between the tumor and paired non-tumor tissues. At the genus level, we observed a notably elevated abundance of Brachybacterium and Haloparvum, coupled with a diminished abundance of Anoxybacillus, Anoxybacillu_A, Deinococcus, NCEH01, and Pseudoxanthomonas_A in the tumor tissues. Meanwhile, at the species level, the non-tumor tissues exhibited an enrichment of Anoxybacillus_A rupiensis, Anoxybacillus flavithermus_G, Klebsiella quasipneumoniae, NCEH01 sp002304505, and Pseudoxanthomonas_A sp004284195. Linear discriminant analysis effect size (LEfSe) identified 29 discriminative features, characterized by significant variations (p<0.5, LDA≥2.0) in relative abundance between the two groups. Furthermore, an analysis of functional predictions utilizing Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) also uncovered disparities in the microbial functional composition.\u0000 \u0000 \u0000 \u0000 This study identified several microorganisms that exhibit differences between MIBC tumor tissue and adjacent non-tumor tissue using 2bRAD-M sequencing, providing some insights into the potential association between the bladder microbiome and cancer.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140714326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colorectal cancer (CRC) is a global challenge, and heat shock protein 90 (HSP90) is identified as a key driver in cancer progression. However, the tumor-promoting mechanism of HSP90 in CRC, particularly HSP90AB1, remains unclear. This study aims to explore and analyze the oncogenic mechanism of HSP90AB1 in CRC and identify potential therapeutic targets. HSP90AB1 expression underwent analysis in CRC cell lines and tissues at mRNA and protein levels. Through the use of shRNA, targeted suppression of HSP90AB1 was achieved in CRC cell lines, enabling analysis of its influence on cell proliferation, invasion, apoptosis, and cell cycle progression. Subsequent investigation focused on elucidating the regulatory relationship between HSP90AB1 and IDO1, employing a combination of bioinformatics approaches and in vitro/vivo experiments. These efforts confirmed IDO1 as a downstream target of HSP90AB1 and provided insight into its role in driving CRC progression. HSP90AB1 exhibits overexpression in both CRC cell lines and tumor tissues (p<0.05). Its downregulation impedes cell proliferation and invasion (p<0.01), promotes apoptosis and cell cycle arrest (p<0.05). Investigation reveals that decreased HSP90AB1 leads to the inhibition of IDO1 (p<0.01), suggesting that IDO1 regulation plays a crucial role in mediating the pro-tumorigenic effects of HSP90AB1. In vivo experiments confirm the substantial reduction in tumor growth upon HSP90AB1 knockdown in xenograft models (p<0.01). However, this tumor-suppressive effect is reversed upon IDO1 overexpression (p<0.01), highlighting IDO1 as a downstream target of HSP90AB1 in CRC progression. HSP90AB1 exerts a regulatory role in the progression of CRC by upregulating IDO1.
{"title":"The HSP90AB1-mediated upregulation of IDO1 can promote the progression of colorectal cancer","authors":"Chenchen Jin, Xuejiao Xu, Tao Li, Chunxue Zhang, Jianqing Peng, Chao Liu, Weifeng Zheng, Xu Zhang","doi":"10.1515/oncologie-2023-0602","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0602","url":null,"abstract":"\u0000 \u0000 \u0000 Colorectal cancer (CRC) is a global challenge, and heat shock protein 90 (HSP90) is identified as a key driver in cancer progression. However, the tumor-promoting mechanism of HSP90 in CRC, particularly HSP90AB1, remains unclear. This study aims to explore and analyze the oncogenic mechanism of HSP90AB1 in CRC and identify potential therapeutic targets.\u0000 \u0000 \u0000 \u0000 HSP90AB1 expression underwent analysis in CRC cell lines and tissues at mRNA and protein levels. Through the use of shRNA, targeted suppression of HSP90AB1 was achieved in CRC cell lines, enabling analysis of its influence on cell proliferation, invasion, apoptosis, and cell cycle progression. Subsequent investigation focused on elucidating the regulatory relationship between HSP90AB1 and IDO1, employing a combination of bioinformatics approaches and in vitro/vivo experiments. These efforts confirmed IDO1 as a downstream target of HSP90AB1 and provided insight into its role in driving CRC progression.\u0000 \u0000 \u0000 \u0000 HSP90AB1 exhibits overexpression in both CRC cell lines and tumor tissues (p<0.05). Its downregulation impedes cell proliferation and invasion (p<0.01), promotes apoptosis and cell cycle arrest (p<0.05). Investigation reveals that decreased HSP90AB1 leads to the inhibition of IDO1 (p<0.01), suggesting that IDO1 regulation plays a crucial role in mediating the pro-tumorigenic effects of HSP90AB1. In vivo experiments confirm the substantial reduction in tumor growth upon HSP90AB1 knockdown in xenograft models (p<0.01). However, this tumor-suppressive effect is reversed upon IDO1 overexpression (p<0.01), highlighting IDO1 as a downstream target of HSP90AB1 in CRC progression.\u0000 \u0000 \u0000 \u0000 HSP90AB1 exerts a regulatory role in the progression of CRC by upregulating IDO1.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140736491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-04DOI: 10.1515/oncologie-2024-0068
Liane Rapatoni, Altacílio Nunes
{"title":"Advances and costs in oncology: where is the balance?","authors":"Liane Rapatoni, Altacílio Nunes","doi":"10.1515/oncologie-2024-0068","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0068","url":null,"abstract":"","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140742067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
While the delay in adjuvant chemotherapy (AC) is known to impact colon cancer outcomes, its effect on rectal cancer is less clear. This study aims to evaluate the influence of AC timing on survival in stage II and III rectal cancer. This retrospective multicenter study enrolled 1,144 patients receiving chemotherapy following resection of stage II–III rectal cancers. The effect of delayed AC on survival was assessed using multivariable Cox models with restricted cubic splines and logistic regression. Compared to patients initiating AC within four weeks postsurgery, those initiating within 5–8 weeks had a similar survival (HR=0.85, 95 % CI=0.66–1.11), whereas those initiating within 8–12 weeks (HR=1.62, 95 % CI=1.05–2.51) or beyond 12 weeks (HR=2.07, 95 % CI=1.21–3.56) had a significantly inferior survival. A delayed time to chemotherapy (>8 weeks) was associated with worse survival in patients aged ≥60 years but not in younger patients (<60 years: HR=1.36; 95 % CI=0.75–2.46, p=0.312; ≥60 years: HR=2.37; 95 % CI=1.56–3.60, p<0.001). Additionally, our exploratory analysis suggested that FOLFOX and FOLFIRI were more effective when starting within 5–8 weeks post-surgery, while CAPEOX and a single agent showed a slight advantage when starting within four weeks. Our findings advocate for initiating AC within eight weeks post-surgery in stage II–III rectal cancer, especially in older patients. Delayed treatment is linked to significantly worse survival outcomes.
{"title":"Time to initiation of adjuvant chemotherapy and survival in patients with stage II and III rectal cancer not receiving total neoadjuvant therapy","authors":"Siyuan Huai, Xuan-zhu Zhao, Shuyuan Wang, Hongzhou Li, Zhen Yuan, Wenwen Pang, Wanting Wang, Qiurong Han, Yao Yao, Tianhao Chu, Zhiqiang Feng, Yanfei Liu, Suying Yan, Leixin Jin, Qinghuai Zhang, Xipeng Zhang, Xuetao Dong, Jun Xue, Chunze Zhang","doi":"10.1515/oncologie-2023-0585","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0585","url":null,"abstract":"\u0000 \u0000 \u0000 While the delay in adjuvant chemotherapy (AC) is known to impact colon cancer outcomes, its effect on rectal cancer is less clear. This study aims to evaluate the influence of AC timing on survival in stage II and III rectal cancer.\u0000 \u0000 \u0000 \u0000 This retrospective multicenter study enrolled 1,144 patients receiving chemotherapy following resection of stage II–III rectal cancers. The effect of delayed AC on survival was assessed using multivariable Cox models with restricted cubic splines and logistic regression.\u0000 \u0000 \u0000 \u0000 Compared to patients initiating AC within four weeks postsurgery, those initiating within 5–8 weeks had a similar survival (HR=0.85, 95 % CI=0.66–1.11), whereas those initiating within 8–12 weeks (HR=1.62, 95 % CI=1.05–2.51) or beyond 12 weeks (HR=2.07, 95 % CI=1.21–3.56) had a significantly inferior survival. A delayed time to chemotherapy (>8 weeks) was associated with worse survival in patients aged ≥60 years but not in younger patients (<60 years: HR=1.36; 95 % CI=0.75–2.46, p=0.312; ≥60 years: HR=2.37; 95 % CI=1.56–3.60, p<0.001). Additionally, our exploratory analysis suggested that FOLFOX and FOLFIRI were more effective when starting within 5–8 weeks post-surgery, while CAPEOX and a single agent showed a slight advantage when starting within four weeks.\u0000 \u0000 \u0000 \u0000 Our findings advocate for initiating AC within eight weeks post-surgery in stage II–III rectal cancer, especially in older patients. Delayed treatment is linked to significantly worse survival outcomes.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140223017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-18DOI: 10.1515/oncologie-2024-0037
Hui Guo, Yuchuan Hou, Chunxi Wang, Jianxun Ding
The realm of cancer therapy has been profoundly altered with the emergence of immune checkpoint blockade (ICB) therapy, providing improved survival prospects for many patients with some cancers. However, the challenge of achieving efficient or sustained therapeutic benefits underscores the critical imperative to optimize ICB strategies. This review elucidates the pivotal role of predictive biomarkers in optimizing precision ICB therapy, deciphering the intricate dynamics associated with the response heterogeneity. Furthermore, it critically examines the application of nanotechnology-driven drug delivery as a promising avenue to amplify ICB efficacy, facilitating controlled and targeted drug release. Recognizing the comprehensive and dynamic interplay among tumor cells, immune cells, and stromal cells has catalyzed the transformative advances in reverse translational research. This approach enables researchers to gain insights into the underlying mechanisms of ICB therapy, therapeutic responses, and resistance mechanisms. The convergence of predictive biomarkers, revolutionary nanotechnology, and reverse translational research emerges as an indispensable focal point, propelling the frontiers of precision oncology within the complex landscape of ICB therapy.
{"title":"How to optimize the immune checkpoint blockade therapy for cancers?","authors":"Hui Guo, Yuchuan Hou, Chunxi Wang, Jianxun Ding","doi":"10.1515/oncologie-2024-0037","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0037","url":null,"abstract":"\u0000 The realm of cancer therapy has been profoundly altered with the emergence of immune checkpoint blockade (ICB) therapy, providing improved survival prospects for many patients with some cancers. However, the challenge of achieving efficient or sustained therapeutic benefits underscores the critical imperative to optimize ICB strategies. This review elucidates the pivotal role of predictive biomarkers in optimizing precision ICB therapy, deciphering the intricate dynamics associated with the response heterogeneity. Furthermore, it critically examines the application of nanotechnology-driven drug delivery as a promising avenue to amplify ICB efficacy, facilitating controlled and targeted drug release. Recognizing the comprehensive and dynamic interplay among tumor cells, immune cells, and stromal cells has catalyzed the transformative advances in reverse translational research. This approach enables researchers to gain insights into the underlying mechanisms of ICB therapy, therapeutic responses, and resistance mechanisms. The convergence of predictive biomarkers, revolutionary nanotechnology, and reverse translational research emerges as an indispensable focal point, propelling the frontiers of precision oncology within the complex landscape of ICB therapy.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140232505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：